| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PPP1R12A; MBS; MYPT1; Protein phosphatase 1 regulatory subunit 12A; Myosin phosphatase-targeting subunit 1; Myosin phosphatase target subunit 1; Protein phosphatase myosin-binding subunit |
| Entrez GeneID | 4659 |
| WB Predicted band size | Calculated MW: 115 kDa; Observed MW: 140 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Monkey |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MYPT1. AA range:661-710 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4条关于Myosin Phosphatase抗体的参考文献及其摘要概括：
---
1. **文献名称**：*Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)*
**作者**：Kimura K, Ito M, Amano M, et al.
**摘要**：该研究揭示了Rho激酶(ROCK)通过磷酸化肌球蛋白磷酸酶靶向亚基(MYPT1)抑制其活性，从而调节平滑肌收缩。文中使用特异性抗MYPT1抗体进行免疫印迹和免疫沉淀，验证了磷酸化位点及调控机制。
---
2. **文献名称**：*Phosphorylation and activation of myosin phosphatase by Rho-kinase*
**作者**：Feng J, Ito M, Ichikawa K, et al.
**摘要**：文章探讨了Rho激酶对肌球蛋白磷酸酶的激活机制，通过抗PP1cδ(肌球蛋白磷酸酶催化亚基)和抗MYPT1抗体，证实了复合体组成及磷酸化依赖的功能变化，为血管收缩调控提供了分子证据。
---
3. **文献名称**：*Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy*
**作者**：Komers R, Oyama TT, Beard DR, et al.
**摘要**：研究利用抗MYPT1磷酸化特异性抗体，检测糖尿病肾病模型中肌球蛋白磷酸酶的活性变化，证明抑制RhoA/ROCK通路可减轻肾小球硬化，抗体用于评估组织内磷酸化状态。
---
4. **文献名称**：*Distinct roles of ROCK and MRCK in myosin phosphorylation and cell migration*
**作者**：Wilkinson S, Paterson HF, Marshall CJ.
**摘要**：通过抗磷酸化MYPT1抗体和肌球蛋白轻链(MLC)抗体，比较了ROCK与MRCK激酶在细胞迁移中的作用，揭示了肌球蛋白磷酸酶活性差异对细胞骨架重塑的影响。
---
这些文献均涉及使用特异性抗体分析肌球蛋白磷酸酶组分(如MYPT1或PP1cδ)的表达、磷酸化及功能，支持其在平滑肌收缩、疾病机制等领域的研究。
Myosin phosphatase (MP) is a key enzyme complex regulating smooth muscle contraction and non-muscle cell motility by dephosphorylating the myosin regulatory light chain (MLC20). Its core subunit structure includes a catalytic protein phosphatase 1 (PP1) and a regulatory subunit, Myosin Phosphatase Target Subunit 1 (MYPT1 or PPP1R12A), which determines substrate specificity and localization. MP activity is modulated by RhoA/ROCK and other signaling pathways, impacting vascular tone, cell migration, and cytokinesis.
Antibodies targeting MP subunits (e.g., MYPT1. PP1) are essential tools for studying its expression, localization, and regulatory mechanisms. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to explore MP's role in physiological processes (e.g., blood pressure regulation) and pathologies such as hypertension, asthma, and cancer metastasis. For instance, reduced MYPT1 expression or inhibitory phosphorylation (e.g., at Thr696/Thr853) is linked to vascular dysfunction. Researchers also utilize these antibodies to investigate cross-talk between MP and other signaling molecules (e.g., PKC, ZIPK). Commercial MP antibodies are typically raised in rabbits or mice, with validation emphasizing specificity against isoform variants and post-translationally modified forms. Proper controls (e.g., knockout samples) are critical due to potential cross-reactivity with related phosphatases.
×
